Abstract Background Early detection of urothelial carcinoma (UCa) remains challenging because of the limitations of current diagnostic methods. The objective of this study was to evaluate a novel, urine‐based H4C6/TWIST1 methylation assay for its diagnostic accuracy in UCa. Methods In a prospective, multicenter study, 743 urine samples (387 patients with UCa and 356 controls) from four hospitals were analyzed. DNA was extracted from 3.5 mL of morning urine, and H4C6/TWIST1 methylation status was assessed by using quantitative polymerase chain reaction analysis. Histopathology served as the reference standard. Results The assay demonstrated high diagnostic accuracy, with 93.02% sensitivity (95% confidence interval, 90.01%–95.35%) and 92.13% specificity (95% confidence interval, 88.83%–94.71%). The positive and negative predictive values were 92.78% and 92.39%, respectively. Performance was particularly strong for high‐grade tumors (97.64%) and muscle‐invasive tumors (97.50%). Diagnostic efficacy was consistent across age, sex, and tumor location, covering both lower and upper urinary tract carcinomas. Conclusions H4C6/TWIST1 methylation detection is a noninvasive, highly accurate, and consistent tool with significant clinical potential for the initial diagnosis and monitoring of UCa across all grades and stages.
Wu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: